2021
Association of pathological complete response rates and TILs in triple-negative breast cancer patients.
Kassem M, Goldstein D, Schnell P, Grimm M, Quiroga D, Miah A, Vargo C, Shinde N, Michael B, Pariser A, Gatti-Mays M, VanDeusen J, Williams N, Stover D, Sardesai S, Wesolowski R, Lustberg M, Ramaswamy B, Tozbikian G, Cherian M. Association of pathological complete response rates and TILs in triple-negative breast cancer patients. Journal Of Clinical Oncology 2021, 39: e12596-e12596. DOI: 10.1200/jco.2021.39.15_suppl.e12596.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-infiltrating lymphocytesInternational TILs Working GroupPathological complete response rateComplete response rateNeoadjuvant chemotherapyLong-term prognosisTNBC patientsBreast cancerAssociation of TILsResponse rateHigh distant recurrence rateOhio State University Comprehensive Cancer CenterTriple-negative breast cancer patientsSingle-institution retrospective analysisHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Residual cancer burden indexRates of breastDistant recurrence ratesPreoperative systemic therapyGrowth factor receptor 2Majority of patientsInvasive ductal cancerBreast cancer patients
2015
Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials
Hicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.Peer-Reviewed Original ResearchConceptsAddition of lapatinibHER2-positive breast cancerNeoadjuvant chemotherapyBreast cancerLymph nodesClinical trialsEarly-stage HER2-positive breast cancerSan Antonio Breast Cancer SymposiumPathologic complete response rateEarly-stage breast cancerResidual invasive cancerResidual invasive carcinomaComplete response rateOperable breast cancerAxillary lymph nodesPathologic complete responseProspective clinical trialsStage breast cancerRates of pCRDual HER2NAC armProspective RCTsCancer SymposiumPCR rateComplete response